An Open-label Phase 2 Study of QL1706 Plus Carboplatin and Etoposide as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 Jan 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Carboplatin (Primary) ; Etoposide (Primary) ; Iparomlimab/tuvonralimab (Primary)
Indications Small cell lung cancer
Focus Adverse reactions
Sponsors Qilu Pharmaceutical

17 Jan 2025 Status changed from active, no longer recruiting to completed.
06 Jun 2023 Results (Apr 18, 2022 to Jul 27, 2022; As of data cutoff (Jan 16, 2023) assessing the safety and efficacy of QL1706 plus carboplatin/etoposide in patients with extensive-stage small-cell lung cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
31 May 2023 According to Qilu Pharmaceutical media release, data from this study selected for the prestigious ASCO 2023 Annual Meeting

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com